*Sponsored by Valion Bio, Inc
A late-stage, highly de-risked TLR5 platform with a non-dilutive government funding pathway, a vertically integrated manufacturing subsidiary, and multiple near-term value-inflecting catalysts
Late-Stage Biopharmaceutical Company with Government-Backed Asset and Potential Multiple Revenue Stream Model
Read the Investor Presentation HERE
______________________________________
Hello Everyone,
There’s a biotech company betting that medicine has been looking in the wrong place. For decades, drug developers have poured resources into the adaptive immune system — antibodies, T-cell therapies, checkpoint inhibitors — while largely ignoring the body’s original defense mechanism: innate immunity, the system that senses danger within minutes and mobilizes before anything else kicks in.
Valion Bio thinks that gap is the opportunity.
The company’s entire pipeline runs through a single molecule, Entolimod, a Toll-like Receptor 5 agonist now in clinical development. Rather than chasing dozens of programs, Valion is going deep on one well-understood mechanism and testing it everywhere the biology suggests it could matter — from Acute Radiation Syndrome to oncology supportive care to early immuno-oncology work.
What sets Valion apart isn’t just the science, though. It’s the infrastructure around it. Through Velocity Bioworks, a wholly owned manufacturing subsidiary in San Antonio, the company controls its own domestic supply chain and generates commercial revenue independent of its clinical pipeline — a level of self-sufficiency most clinical-stage biotechs simply don’t have. And its closest partners aren’t typical biotech collaborators: BARDA, NIAID, DTRA, the Department of War, and major oncology centers, the institutions actually on the front lines of the problems Valion is trying to solve.
Entolimod is the world’s most advanced TLR5 agonist — for acute radiation syndrome under the FDA Animal Rule pathway, oncology supportive care, and immuno-oncology. The company acquired a $140M+ de-risked asset including an active IND, FDA Fast Track, and Orphan Drug designation. Its wholly owned CDMO subsidiary, Velocity Bioworks, provides domestic biomanufacturing and a path to non-dilutive revenue.
A TLR5 agonist in clinical development — where innate immunity matters most
Mechanism
Entolimod is a Toll-like Receptor 5 (TLR5) agonist. TLR5 is a pattern-recognition receptor on the surface of immune and epithelial cells that, when activated, triggers NF-kB signaling — a central pathway in the body’s innate immune response.
Activation of this pathway has been shown in nonclinical models to influence multiple biological processes associated with the response to radiation exposure, including modulation of cell survival pathways, support of progenitor cell recovery in affected tissues, and effects on immune cell activity, including NK and T cells.
Entolimod is being investigated across multiple indications where activation of this pathway may support cellular and tissue responses. Each indication will require its own clinical development program and regulatory submissions.
Lead indication: Acute Radiation Syndrome
High-dose radiation exposure — whether from a nuclear incident, a radiological weapon, or an accident at an industrial or medical facility — causes Acute Radiation Syndrome (ARS): a cascade of bone marrow failure, gastrointestinal complications, and epithelial damage.
Entolimod is being developed as a medical countermeasure for ARS under the FDA’s Animal Rule — a regulatory framework designed for treatments where human efficacy trials are not ethical or feasible. The program has received Fast Track and Orphan Drug designations from the FDA. The development program includes nonclinical efficacy studies, clinical safety data, and translational work to support dose selection, and continues to advance toward potential regulatory submission.
In a post-hoc pooled analysis of the RS-23 animal study conducted under the FDA Animal Rule, Entolimod was associated with an odds ratio of 7.9. A 25-hour post-exposure treatment window has been observed in nonclinical models. Note: RS-23 was not accepted by FDA as a pivotal study.
Expanded Indications
Neutropenia is a life-threatening drop in white blood cells that affects a significant proportion of patients undergoing chemotherapy or radiation therapy. Currently approved agents include G-CSF products such as Neupogen and Neulasta, which address multiple clinical contexts including chemotherapy-induced neutropenia, stem cell mobilization, severe chronic neutropenia, and mitigation of damage from ARS.
Entolimod is being investigated for its potential to activate innate immune pathways and support tissue responses to injury. In nonclinical models, this activity has been associated with effects in both hematopoietic and gastrointestinal tissues. The program is in early-stage development for oncology supportive care. The global market for oncology supportive-care therapies is estimated at more than $22 billion.
Lymphocyte exhaustion
Chronic infections and cancers can drive T-cells and other lymphocytes into a state of functional exhaustion — reduced cytokine production, reduced proliferative capacity, and loss of effector function. Entolimod’s ability to activate innate immune signaling offers a mechanistic rationale for restoring immune function in these states.
Immune function in older adults
As people age, immune responses may become less robust and less predictable, which can contribute to increased vulnerability to infection and reduced vaccine responsiveness. Entolimod has been evaluated in a Phase 2 study at Mayo Clinic in healthy older adults receiving influenza vaccination. These data support continued exploratory research into the potential effects of TLR5 activation on age-related immune function.
Chronic Radiation Syndrome
Chronic Radiation Syndrome results from prolonged, lower-dose radiation exposure — a clinical condition distinct from ARS and without effective treatment. Entolasta, a second-generation follow-on to Entolimod, is being advanced through IND-enabling studies for chronic indications including Chronic Radiation Syndrome.
Domestic biomanufacturing. Vertically integrated. Operating in alignment with applicable regulatory requirements
Velocity Bioworks is Valion Bio’s wholly owned contract development and manufacturing organization (CDMO) — a U.S.-based biomanufacturing facility that supports Valion Bio’s own supply chain and generates independent commercial revenue serving outside clinical-stage biotech clients.
Why it Matters
Most clinical-stage biotech companies depend on third-party manufacturers — a structural consideration in timelines, costs, and supply chain resilience. Velocity Bioworks supports Valion Bio’s own pipeline and operates as a revenue-generating strategic asset.
For federally funded biodefense programs and engagement with federal biodefense agencies, domestic biomanufacturing operating in alignment with applicable regulatory requirements is an important capability. Velocity was built with that standard in mind.
What Velocity Does
Velocity Bioworks operates from San Antonio, Texas, and provides end-to-end support for clinical-stage biologics development and manufacturing, including:
- cGMP drug substance and cell bank manufacturing.
- Upstream and downstream process development and optimization.
- Analytical testing, assay development, and qualification.
- Quality control and stability testing.
- Microbial expression systems.
- Technology transfer and program management.
- Regulatory compliance support.
Built for speed to clinic
Velocity is structured around a single operating principle: translate defined program goals into scalable manufacturing processes and robust analytical strategies without compromising quality or timeline. The team designs programs to support near-term clinical milestones while meeting every applicable quality and regulatory requirement.
Two assets. Multiple indications. One mechanism.
Entolimod and its second-generation follow-on, Entolasta, together form a pipeline of innate immune modulating therapies being investigated across biodefense, oncology supportive care, and immuno-oncology. More than $140 million has been invested across the platform to date.
TLR5 platform: one receptor, multiple disease states
Targeted activation of the TLR5 receptor drives a coordinated biological response across multiple tissue systems — enabling one mechanism to address multiple clinical indications:
- Hematopoiesis — bone marrow recovery (neutrophils, platelets).
- GI protection — intestinal integrity after radiation injury or chemotherapy.
- NK / T-cell activation — anti-tumor immunity and immuno-oncology combination potential.
- Anti-apoptotic signaling — cell survival in bone marrow and GI tissues.
- Endothelial repair — vascular integrity after radiation exposure.
- Immune modulation — reversing immunosenescence (Mayo Clinic Phase II).
Development milestones
Anticipated development milestones across the next 18 to 24 months include:
- Initiation of Neutropenia clinical studies (timing subject to IND readiness)
- Entolasta IND-enabling studies
- Entolasta drug substance availability (targeted end of 2026)
- GMP Entolimod for bioequivalence study (targeted 1Q2027)
- Entolasta pre-IND meeting (targeted 1Q2027)
- GMP manufacturing validation activities (targeted 2027)
Milestone timing is subject to clinical, regulatory, and operational factors and may change. Entolasta is expected to be treated by FDA as a new molecular entity and will require its own clinical development program and regulatory submissions.
Market context
The TLR5 platform is being investigated across therapeutic areas with significant market potential, including Acute Radiation Syndrome (estimated $5.5B, 5.2% CAGR), Neutropenia and oncology supportive care (estimated $22.3B, 4.8% CAGR), and Immuno-Oncology solid tumors (estimated $120B, 16.3% CAGR). Market estimates are based on industry sources and do not reflect Valion Bio revenue projections.
NEWS
Apr 23, 2026
Apr 15, 2026
Mar 31, 2026
Tivic CEO To Present at the Upcoming Emerging Growth’s April 2026 Virtual Conference
Mar 27, 2026
Mar 26, 2026
Tivic Reports Full Year 2025 Results
Mar 25, 2026
Tivic Health CEO Letter to Shareholders
Mar 24, 2026
Mar 20, 2026
Mar 4, 2026
Tivic and BARDA Continue Discussions of Entolimod for Acute Radiation Syndrome on March 10
Feb 18, 2026
Tivic, BARDA Discuss Entolimod(TM) for Acute Radiation Syndrome at TechWatch Meeting
Jan 28, 2026
Jan 26, 2026
Jan 23, 2026
Tivic CEO To Present at the Upcoming Emerging Growth’s January 2026 Virtual Conference
Jan 20, 2026
Jan 12, 2026
MANAGEMENT
SINCERELY,
DISCLAIMER
MicroCapAlerts.io is owned by Dedicated Investors, LLC who is a publisher (the “Publisher”) of favorable information (the “Information”) about publicly traded companies (collectively the “Issuers”) listed on the NASDAQ Stock Exchange (“NASDAQ”), New York Stock Exchange (“NYSE”) and the OTC Markets is a paid advertisement. The Publisher lists its specific compensation at the bottom of this Disclaimer.
The Persons who pay us (“Paying Party”) to publish the Information and their affiliates may hold and control a significant amount of the public float and believe that if potential investors receive favorable information about the Issuers, investors will purchase the Issuers’ shares, including the shares that the Paying Party wants to sell. The Information is neither a solicitation to buy nor an offer to sell securities. The Information is not intended to be used as a source of information for making an investment decision. The Information is not intended and should not be used for trading or investment purposes.
Because the Publisher is paid to disseminate the Information to the public, the Publisher is required by the securities laws, including Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose certain information to you regarding its compensation, including the nature and amount of compensation. The Paying Party and its affiliates may engage in buying and selling of the Issuers’ securities before, during and after the Publication of the Information.
The Information provides de minimis information about the Issuers and is only a brief favorable snapshot of the Issuers subject to the Information. The Information consists of only positive content and does not include any negative information about the Issuers whatsoever; accordingly, you should consider the Information to be one-sided and not balanced, complete, accurate, truthful or reliable. The Publisher is not liable for your use of the Information or any success or failure that is directly or indirectly related to your use of the Information, including misinformation, omissions, errors or delays in providing or updating the Information, or for any actions taken by third parties in reliance upon the Information.
The Publisher is not objective or independent, and its publishing of the Information involves actual and material conflicts of interest, including: (i) the Publisher is paid to publish favorable information about the Issuers; (ii) the Publisher does not publish negative information because it is not paid to do so; and (iii) the Publisher is paid to publish the (favorable) Information about the Issuers advising others, including you, to purchase the Issuers’ securities; and while doing so, the Paying Party may plan to sell their shares of the Issuers.
The Information published by the Publisher may recommend that investors buy the Issuers’ shares while the Paying Party and/or their affiliates sell their shares of the Issuers. When the Paying Party sells their shares, the Issuers’ stock price may decline and thereby dramatically reduce the price at which investors can sell their shares. As such, investors who purchase the Issuers’ shares during the Publication of the Information will likely pay inflated prices. The Paying Party may sell the Issuers’ securities for less than the target prices set forth in the Information. The Paying Party and its affiliates may make substantial profits by selling their securities during the Publication of the Information while investors experience losses.
The Publisher makes no warranty or representation about the Information, including its completeness, accuracy, truthfulness or reliability, and disclaims, expressly and impliedly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the information is at your own risk. The Information is provided “as is” without any warranties of any kind without limitation. The Publisher does not verify or confirm any portion of the Information and does not conduct any due diligence or research on any aspect of the Information, including the completeness, accuracy, truthfulness or reliability of the Information.
Investors should not rely upon the Information for any purpose and should contact a licensed investment advisor and their legal advisor and review all documents about the Issuers with the assistance of such advisors, including documents publicly filed on www.sec.gov and http://www.OTCMarkets.com to obtain information about the Issuers.
Before investing in any public company, you should conduct your own in-depth investigation with the assistance of your legal, tax and investment advisors of the Issuers’ financial condition, operations, management, products or services, trends in the industry, the Issuers’ trading history, short sale positions and risks that may be material to its business and other information you and your advisors deem material to an investment decision. This investigation should include, but not be limited to, a review of available public sources and information you receive directly from http://www.OTCMarkets.com and www.sec.gov.
The Publisher is not and does not act in the capacity of any of the following and is not qualified to do so; as such, you should not construe the Publisher’s activities as involving any of the following:
▪ An independent advisor or consultant;
▪ Providing investment advice or acting in the capacity of an investment adviser or engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal or state level;
▪ Broker-dealer activities or acting in the capacity of a registered representative or broker;
▪ Stock picker;
▪ Securities trading expert;
▪ Securities researcher or analyst;
▪ Financial planner or financial planning;
▪ Provider of stock recommendations;
▪ Provider of advice about buying and selling or holding recommendations as to specific securities; or
▪ Making an offer or sale of securities or solicitation to purchase securities.
An investment in the Issuers involves a high degree of risk and uncertainties and may be subject to extreme volume and price volatility, especially during the Publication of the Information. Favorable past performance of the Issuers does not guarantee future results. If you purchase the securities of the Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Issuers include but are not limited to the risks stated below.
▪ The Information is not a solicitation or recommendation to buy, sell or hold securities, and the Publisher does not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. The Publisher conducts no due diligence or investigation of the Information or the Issuers and does not receive any verification from any party regarding the Information.
▪ If the Publisher publishes any percentage gain of the Issuers’ share from the previous day’s close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.
▪ The Information may contain statements that Issuers’ stock price has increased over a certain period of time, which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon such information in your analysis of the present or future potential of the Issuers or its securities.
▪ The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Issuers’ future stock price or future financial performance.
▪ You may encounter difficulties determining what, if any, portions of the Information are material or nonmaterial, making it all the more imperative that you conduct your own independent investigation of the Issuers and its securities with the assistance of your legal, tax and financial advisor.
▪ If the Information states that its securities are consistent with the future economic trends or even if your independent research indicates as such, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and government may react in unforeseen ways and be affected by behavioral biases that Publisher is unable to predict; (c) human and social factors may outweigh future economic trends that Publisher states may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in such economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of fully new circumstances and situations in which uncertainty becomes reality rather than of predictive economic quality; or (f) if the trends involve a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies.
▪ The Information contains forward-looking statements, i.e., statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as expects, will, anticipates, and estimates; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Issuers with the assistance of your lawyer, tax advisor and investment advisor as well as any such forward-looking statements. Any forward-looking statements made in the Information are limited to the time period in which they are made, and the Publisher does not undertake to update forward-looking statements that may change at any time.
▪ The Information is presented only as a brief snapshot of the Issuers and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Issuers and its securities and to consult your financial, legal or other advisor(s) and avail yourself of the filings and information that may be accessed at www.sec.gov or other electronic medium, including: (a) reviewing Information and Disclosure Statements and unaudited financial reports filed with the www.otcmarkets.com; (b) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (c) investment guides at www.sec.gov and www.finra.org. You should always be concerned that the Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative signs at otcmarkets.com. You should only invest with the assistance of your attorney, lawyer and tax advisor after they have conducted exhaustive due diligence on the particular Issuer and its trading activity.
▪ The Publisher may hire third-party service providers and stock promoters to electronically disseminate live news about the Issuers, yet the Publisher has no control over the content of and does not verify the information that these service providers publish.
The Publisher or its officers, directors, owners, managers, affiliates and control persons were paid to publish the Information about the issuers identified below:
Name of Issuer: 3rd party on behalf of Valion Bio, Inc
Amount of Cash Compensation: twenty thousand usd
Period of Publication of Information: One day campaign beginning and ending on July twenty second twenty twenty six
Where Information is Published: MicroCapAlerts.io Website, Email Campaign, SMS Campaign, Social Media including but not limited to: Youtube, X, Tiktok, Instagram, Stock Twits, Reddit, Discord.
By reading the Information and visiting the Platform, you agree you have not relied on the Information and agree to indemnify, defend and hold the Publisher harmless from any liability for any claimed direct, indirect, incidental, punitive, or consequential damages pertaining to your receipt of the Information without limitation.
Leave a Reply